This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

This study has been completed.
Information provided by (Responsible Party):
Alphonse Taghian, MD, PhD, Massachusetts General Hospital Identifier:
First received: September 11, 2009
Last updated: April 7, 2017
Last verified: April 2017
The purpose of this study is to evaluate radiation therapy directed to a small region of the breast in women who were recently diagnosed with early stage invasive breast cancer.

Condition Intervention Phase
Breast Cancer Radiation: Interstitial Implant Brachytherapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant

Resource links provided by NLM:

Further study details as provided by Alphonse Taghian, MD, PhD, Massachusetts General Hospital:

Primary Outcome Measures:
  • To determine if interstitial implant brachytherapy to radical radiation doses is feasible following wide local excision of T1N0 breast carcinoma [ Time Frame: 3 years ]

Enrollment: 45
Study Start Date: June 1997
Study Completion Date: May 2013
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Radiation: Interstitial Implant Brachytherapy
    Via tubes placed at the time of wide local excision delivered over 5 days
Detailed Description:
  • When participants undergo surgery to remove the tumor (lumpectomy), it will be followed by the placement of small flexible tubes throughout the region surrounding the site of operation. These tubes will remain in place for 7-9 days following the surgery.
  • The first 2-3 days, the tubes will not contain radioactivity. This time is used to do all the calculations necessary for treatment and to check the findings in the breast tissue that was removed. After 2-3 days, the tubes will be filled with a radioactive wire which will remain in place for the next 5 days. During this period of time, participants will be required to remain within the hospital. At the end of these 5 days, the radioactive wires and tubes will be removed.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Low risk of multifocal disease within the breast whose tumor location is favorable for brachytherapy catheter placement
  • Diagnosis of invasive breast carcinoma (biopsy or fine needle aspiration cytology) and be clinical stage T1N0 (primary tumor < 2cm, clinically negative nodes)
  • Location of primary tumor is not immediately adjacent to the nipple of chest wall
  • No evidence of two or more separate tumors within the breast
  • All histologic types and pathologic grades of primary tumor
  • No extensive intraductal component (substantial intraductal carcinoma away from the primary tumor location)
  • No lymphatic or vascular invasion
  • Lymph node staging by sentinel node excision or axillary dissection confirms node negative status (If node positive, implant is used to deliver boost to tumor bed)
  • Assessment of final surgical margins should be predominantly negative, but a single small region of focal positivity is allowable as it is for whole breast radiation
  • 18 years of age or older

Exclusion Criteria:

  • Tumor is too close to the chest wall to allow placement of catheters
  • Contraindications to radiation therapy are present, including a history of scleroderma, systemic lupus or other active connective tissue disease, pregnancy, or prior chest wall radiation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00977275

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Alphonse Taghian, MD, PhD Massachusetts General Hospital
  More Information

Responsible Party: Alphonse Taghian, MD, PhD, Chief Breast Radiation Oncology, MGH, Massachusetts General Hospital Identifier: NCT00977275     History of Changes
Other Study ID Numbers: 97-585
Study First Received: September 11, 2009
Last Updated: April 7, 2017

Keywords provided by Alphonse Taghian, MD, PhD, Massachusetts General Hospital:
early stage invasive breast cancer
Partial breast irradiation
interstitial implant

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 18, 2017